title: Comparisons of the effects of 12-week administration of miglitol and voglibose on the responses of plasma incretins after a mixed meal in Japanese type 2 diabetic patients.
abstract: To compare the effects of miglitol [an alpha-glucosidase inhibitor (AGI) absorbed in the intestine] and voglibose (an AGI not absorbed) on plasma glucagon-like peptide-1 (GLP-1) and gastric inhibitory polypeptide (GIP) levels, 26 and 24 Japanese type 2 diabetic patients were randomly assigned to receive miglitol or voglibose, respectively. After 12-week administration of both drugs, during 2-h meal tolerance test, plasma glucose, serum insulin and total GIP were significantly decreased and active GLP-1 was significantly increased. Miglitol group showed a significantly lower total GIP level than voglibose group. Miglitol, but not voglibose, significantly reduced body weight (BW). In all participants, the relative change in BW was positively correlated with that of insulin significantly and of GIP with a weak tendency, but not of GLP-1. In conclusion, both drugs can enhance postprandial GLP-1 responses and reduce GIP responses. The significant BW reduction by miglitol might be attributable to its strong GIP-reducing efficacy.
authors: Department of Endocrinology, Diabetes and Geriatric Medicine, Akita University Graduate School of Medicine, Hondo 1-1-1, Akita, Japan. narita@med.akita-u.ac.jp
authors: T
authors: T
authors: Narita
authors: H
authors: H
authors: Yokoyama
authors: R
authors: R
authors: Yamashita
authors: T
authors: T
authors: Sato
authors: M
authors: M
authors: Hosoba
authors: T
authors: T
authors: Morii
authors: H
authors: H
authors: Fujita
authors: K
authors: K
authors: Tsukiyama
authors: Y
authors: Y
authors: Yamada
mesh_terms: D017485:1-Deoxynojirimycin / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology; D044466:Asian People; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy* / Q000378:metabolism; D004334:Drug Administration Schedule; D005260:Female; D005749:Gastric Inhibitory Polypeptide / Q000187:drug effects; D052216:Glucagon-Like Peptide 1 / Q000187:drug effects; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000494:pharmacology*; D054795:Incretins / Q000097:blood*; D007294:Inositol / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology; D008297:Male; D008875:Middle Aged; D009765:Obesity / Q000097:blood / Q000188:drug therapy* / Q000378:metabolism; D019518:Postprandial Period
chemical_list: D007004:Hypoglycemic Agents; D054795:Incretins; C045621:miglitol; D017485:1-Deoxynojirimycin; D007294:Inositol; D005749:Gastric Inhibitory Polypeptide; D052216:Glucagon-Like Peptide 1; C102817:voglibose